Status:
ACTIVE_NOT_RECRUITING
Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination
Lead Sponsor:
University of Aarhus
Conditions:
Healthy
Cytotoxicity
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Investigating cytotoxicity of yellow fever specific CD8 T cells following YF-17D vaccination and the following licensing of these epitope-specific CD8 T cells
Detailed Description
CD: cluster of differentiation YF: yellow fever
Eligibility Criteria
Inclusion
- Age between 18 to 60 years
- Informed consent given
Exclusion
- Fever (orally \>37,5 C) on day of vaccination
- Immunosuppressants
- Pregnant or breast feeding
- Severe immunodeficiency
- Known thymus dysfunction
- Allergy against egg
- Known haemophilia
- Previous severe reaction to vaccine
- Not willing to use anticonceptives 4 weeks after vaccination
Key Trial Info
Start Date :
October 8 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04083430
Start Date
October 8 2019
End Date
December 15 2025
Last Update
March 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark